Prenatal screening for Down syndrome - Current and future methods

被引:7
作者
Canick, JA [1 ]
Saller, DN
Lambert-Messerlian, GM
机构
[1] Brown Univ, Sch Med, Div Prenatal & Special Testing, Dept Pathol & Lab Med,Womens & Infants Hosp, Providence, RI 02905 USA
[2] W Virginia Univ, Sch Med, Div Maternal Fetal Med, Dept Obstet & Gynecol, Morgantown, WV 26506 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0272-2712(03)00025-8
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Second-trimester serum screening for Down syndrome has had a relatively long clinical life, beginning in the mid-1980s and continuing to the present day. In the past few years, however, new screening methods that involve testing just a few weeks earlier and the integration of first-trimester and second-trimester markers have been proposed and are being used. These improved methods have begun the transition to better and hopefully safer prenatal screening. In the past, as many as 1 in 10 pregnant women learned that they were at increased risk of having a baby with a serious birth defect and had to decide whether to have an invasive diagnostic procedure. Now, screening methods are at the point where as few as 1 in 50 or 1 in 100 pregnant women are found to be at increased risk. The ultimate goal in screening is to make noninvasive testing methods so safe that only those few women who are found to be at the very highest risk will need to face the uncertainty of invasive procedures. In the next few years, that goal will probably be achieved.
引用
收藏
页码:395 / +
页数:18
相关论文
共 66 条
[1]   Dimeric inhibin a as a marker for Down's syndrome in early pregnancy [J].
Aitken, DA ;
Wallace, EM ;
Crossley, JA ;
Swanston, IA ;
vanPareren, Y ;
vanMaarle, M ;
Groome, NP ;
Macri, JN ;
Connor, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (19) :1231-1236
[2]  
*AM COLL OBST GYN, 2001, ACOG PRACT B, V27
[3]   Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement [J].
Benn, PA ;
Gainey, A ;
Ingardia, CJ ;
Rodis, JF ;
Egan, JFX .
PRENATAL DIAGNOSIS, 2001, 21 (08) :680-686
[4]   ABNORMAL MATERNAL SERUM CHORIONIC-GONADOTROPIN LEVELS IN PREGNANCIES WITH FETAL CHROMOSOME-ABNORMALITIES [J].
BOGART, MH ;
PANDIAN, MR ;
JONES, OW .
PRENATAL DIAGNOSIS, 1987, 7 (09) :623-630
[5]  
Bradley LA, 1999, AM J MED GENET, V82, P355, DOI 10.1002/(SICI)1096-8628(19990212)82:4<355::AID-AJMG16>3.0.CO
[6]  
2-4
[7]   LOW MATERNAL SERUM LEVELS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A (PAPP-A) IN THE 1ST TRIMESTER IN ASSOCIATION WITH ABNORMAL FETAL KARYOTYPE [J].
BRAMBATI, B ;
MACINTOSH, MCM ;
TEISNER, B ;
MAGUINESS, S ;
SHRIMANKER, K ;
LANZANI, A ;
BONACCHI, I ;
TULUI, L ;
CHARD, T ;
GRUDZINSKAS, JG .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (04) :324-326
[8]   LOW 2ND TRIMESTER MATERNAL SERUM UNCONJUGATED ESTRIOL IN PREGNANCIES WITH DOWNS-SYNDROME [J].
CANICK, JA ;
KNIGHT, GJ ;
PALOMAKI, GE ;
HADDOW, JE ;
CUCKLE, HS ;
WALD, NJ .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1988, 95 (04) :330-333
[9]   PRENATAL SCREENING FOR TRISOMY-18 IN THE 2ND TRIMESTER [J].
CANICK, JA ;
PALOMAKI, GE ;
OSATHANONDH, R .
PRENATAL DIAGNOSIS, 1990, 10 (08) :546-548
[10]   First trimester screening for aneuploidy: Serum biochemical markers [J].
Canick, JA ;
Kellner, LH .
SEMINARS IN PERINATOLOGY, 1999, 23 (05) :359-368